FDA Shares Safety Data About ‘Adverse Events’ From Compounded Weight Loss Drugs

Hundreds of people taking compounded GLP-1 drugs — unapproved versions of brand-name weight loss medications — have reported “adverse events,” with some health issues requiring hospitalization, according to the U.S. Food and Drug Administration (FDA).

As of July 31, 2025, the agency has received a total of 605 reports of adverse events with compounded semaglutide, the active ingredient in Wegovy and Ozempic, and a total of 545 adverse event reports for tirzepatide, the active ingredient in Mounjaro and Zepbound, the FDA said in a statement.

The true number of safety issues with compounded GLP-1 drugs is likely higher because many pharmacies that make these products aren’t required to report adverse events to regulators, the FDA said.

Dosing Errors May Be More Common With Compounded GLP-1s

Multiple adverse event reports were related to dosing mistakes with compounded semaglutide injections, which resulted from patients self-administering incorrect doses or healthcare providers miscalculating doses, the FDA said.

Melanie Jay, MD, a professor at New York University and the director of the NYU Langone Comprehensive Program on Obesity Research, points out that most brand-name drugs come in prefilled pens that make it relatively simple to “dial up” the right dose by twisting a knob. People using compounded GLP-1s, however, typically draw the medication from a vial with a syringe.

Great Job Lisa Rapaport & the Team @ google-discover Source link for sharing this story.

#FROUSA #HillCountryNews #NewBraunfels #ComalCounty #LocalVoices #IndependentMedia

Felicia Owens
Felicia Owenshttps://feliciaray.com
Happy wife of Ret. Army Vet, proud mom, guiding others to balance in life, relationships & purpose.

Latest articles

spot_img

Related articles

LEAVE A REPLY

Please enter your comment!
Please enter Your First & Last Name here

Leave the field below empty!

spot_img
Secret Link